Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVX70561
- Development stage
- Preclinical
- Lead developer
- AstriVax Therapeutics
- Modality
- Vaccines & Immunotherapeutics
01
Overview
AVX70561 is an investigational therapeutic HPV immunotherapy being developed by AstriVax for the treatment of persistent human papillomavirus (HPV) infection and prevention of progression to HPV-related precancerous lesions and solid tumors.[2][3] It is based on AstriVax’s Launch-IT viral vector vaccine platform and is designed to elicit a strong, antigen-specific CD8+ T-cell response against HPV-infected cells, thereby clearing persistent infection and reducing oncogenic risk.[2] The program is currently at the discovery to preclinical proof-of-concept stage, with development focused on neoplastic indications driven by persistent HPV infection.[1][2][3]
Beyond the preview
Go deeper on AVX70561.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVX70561.